Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)

Inclusion Criteria: * Patients of either sex, older than 18 years, with no immunological risk (PRA\<20% and absence of DSA), who receive their first deceased donor or living donor KT. * Presence of BL, excluding isolated inflammation (t0, i\>0) and isolated tubulitis (t\>0, i0). * Patients receiving tacrolimus in combination with mycophenolic acid (MPA) and steroids. * Absence of clinical or subclinical and histological immunological dysfunction before randomization. * Absence of de novo DSA anti-HLA antibodies at the time of randomization. * Provision of written informed consent. * Acceptance of efficient contraception in women. Exclusion Criteria: * Recipients of a multi-organ transplant. * Re-transplants. * Patients without inflammation in the third month protocol biopsy (i0,t0), or with isolated inflammation without tubulitis (t0,i\>0) or isolated tubulitis without inflammation (t\>0,i0). * Presence of DSA antibodies before transplantation or at randomization. * Cold ischemia time \>30 hours. * Serum creatinine \>2.5 mg/dl or proteinuria \>1 g/day at randomization. * Presence of significant thrombopenia (\<100,000/mm3) or leukopenia (\<3000 mm/3) at randomization. * Previous episode of clinical or subclinical rejection (≥IA) before randomization. * CMV disease in the first three months after transplantation. * BK-polyomavirus nephropathy at randomization. * Recurrent or de novo glomerulonephritis. * Treatment with immunosuppressive drugs other than those in this clinical trial. * Patients who are positive for the human immunodeficiency virus (HIV) or with severe systemic infection, who, in the opinion of the investigator, require continued therapy. * Previous (within the last 5 years) or present malignancy, except excised basal or squamous cell carcinoma.